Retirement Systems of Alabama Sells 9,184 Shares of Halozyme Therapeutics, Inc. $HALO

Retirement Systems of Alabama trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 371,195 shares of the biopharmaceutical company’s stock after selling 9,184 shares during the quarter. Retirement Systems of Alabama owned about 0.32% of Halozyme Therapeutics worth $27,223,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Root Financial Partners LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $25,000. Richardson Financial Services Inc. boosted its position in Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Halozyme Therapeutics during the second quarter worth approximately $32,000. Employees Retirement System of Texas acquired a new position in Halozyme Therapeutics during the second quarter valued at approximately $34,000. Finally, First Horizon Corp bought a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $56,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 2.9%

NASDAQ HALO opened at $69.22 on Monday. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $79.50. The stock has a market cap of $8.14 billion, a PE ratio of 14.57, a PEG ratio of 0.30 and a beta of 0.94. The firm has a 50-day simple moving average of $68.78 and a 200 day simple moving average of $68.02. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. During the same quarter in the prior year, the firm posted $1.27 EPS. The company’s revenue for the quarter was up 22.1% on a year-over-year basis. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on HALO. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. The Goldman Sachs Group restated a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, December 29th. Citizens Jmp boosted their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Friday, December 19th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $78.80.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at $50,721,994.47. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,661 shares of company stock valued at $3,139,257 over the last ninety days. 2.90% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.